Oncology – the current landscape and what it means for the futureThe WHO reports that in 2015, cancer was the second highest cause of death globally – responsible for Share XOncology – the current landscape and what it means for the futurehttps://pharmaphorum.com/partner-content-oncology/oncology-current-landscape-means-future/
What oncologists need from you when launching a new therapyAt the end of 2015 there were almost 600 new oncology-related molecules in late-stage development, so it is Share XWhat oncologists need from you when launching a new therapyhttps://pharmaphorum.com/partner-content/oncologists-need-launching-new-therapy/
How RACE legislation is changing the face of pediatric oncology in the USOn August 12 of this year the US senate unanimously passed the Race to Accelerate Cures and Equity Share XHow RACE legislation is changing the face of pediatric oncology in the UShttps://pharmaphorum.com/partner-content-oncology/race-legislation-changing-face-pediatric-oncology-us/
11/23/2017The evolution of pharma social media intelligenceIs your company a fully mature user of intelligence from social media, or is it still not tapping Share XThe evolution of pharma social media intelligencehttps://pharmaphorum.com/debates-insight-sales-marketing/evolution-pharma-social-media-intelligence/
Biosimilars in oncology: a €2billion opportunity for European healthcareIQVIA’s Murray Aitken examines the potential for savings from a new wave of oncology biosimilars – but says Share XBiosimilars in oncology: a €2billion opportunity for European healthcarehttps://pharmaphorum.com/views-and-analysis/biosimilars-oncology-european-healthcare/
